Fennec Pharmaceuticals Inc. (FENC): Price and Financial Metrics


Fennec Pharmaceuticals Inc. (FENC)

Today's Latest Price: $7.43 USD

0.25 (-3.26%)

Updated Jan 27 4:00pm

Add FENC to Watchlist
Sign Up

Overall POWR Rating

Sign Up to See Ratings...FREE!

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

FENC Stock Price Chart Interactive Chart >

Price chart for FENC

FENC Price/Volume Stats

Current price $7.43 52-week high $10.67
Prev. close $7.68 52-week low $4.65
Day low $7.30 Volume 185,443
Day high $7.83 Avg. volume 86,759
50-day MA $7.67 Dividend yield N/A
200-day MA $7.43 Market Cap 191.77M

Fennec Pharmaceuticals Inc. (FENC) Company Bio

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, a water soluble thiol compound that acts as a chemical reducing agent, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was founded in 1996 and is based in Research Triangle Park, North Carolina.

Most Popular Stories View All

• #1 Ingredient for Picking the Best Stocks

• Is General Motors the Next Tesla?

• 2 Stocks That Could be Acquisition Targets in 2021: DropBox, Yelp

• 3 "Strong Buy" Tech Stocks with PE Ratios Under 15

• Forget Alibaba, Buy These 4 Asian E-Commerce Stocks Instead

View All Top Stories

FENC Latest News Stream

Event/Time News Detail
Loading, please wait...
View All FENC News

FENC Latest Social Stream

Loading social stream, please wait...

View Full FENC Social Stream

Latest FENC News From Around the Web

Below are the latest news stories about Fennec Pharmaceuticals Inc that investors may wish to consider to help them evaluate FENC as an investment opportunity.

Here is What Hedge Funds Think About Fennec Pharmaceuticals Inc. (FENC)

Most investors tend to think that hedge funds and other asset managers are worthless, as they cannot beat even simple index fund portfolios. In fact, most people expect hedge funds to compete with and outperform the bull market that we have witnessed in recent years. However, hedge funds are generally partially hedged and aim at […]

Yahoo | December 3, 2020

Fennec Pharmaceuticals (NASDAQ:FENC) Downgraded by Zacks Investment Research to Strong Sell

Zacks Investment Research downgraded shares of Fennec Pharmaceuticals (NASDAQ:FENC) from a hold rating to a strong sell rating in a research report released on Thursday, Zacks.com reports. According to Zacks, “Fennec Pharmaceuticals Inc. is a clinical-stage biotechnology company. It is focused on the development of Sodium Thiosulfate for the prevention of ototoxicity from cisplatin in […]

Transcript Daily | November 20, 2020

Fennec Pharmaceuticals EPS misses by $0.05 (NASDAQ:FENC)

Fennec Pharmaceuticals (NASDAQ:FENC): Q3 GAAP EPS of -$0.24 misses by $0.05. Cash and cash equivalents were $33.2 million as of September 30, 2020. Press R

Seeking Alpha | November 16, 2020

EFFECT - FENNEC PHARMACEUTICALS INC. (0001211583) (Filer) - Stocks News Feed

Accepted 2020-11-12 00:15:19 Documents Stock Market Shirts | Stock Trading Mugs | Stock Trader Decor | Investing Books 1 Effectiveness Date 2020-11-10 Registration Form S-3 Document Format Files Mailing Address PO BOX 13628 68 TW ALEXANDER DRIVE RESEARCH TRIANGLE PARK NC 27709 Business Address PO BOX 13628 68 TW ALEXANDER DRIVE RESEARCH TRIANGLE PARK NC… Read More »EFFECT – FENNEC PHARMACEUTICALS INC. (0001211583) (Filer)

Stocks News Feed | November 11, 2020

DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Fennec Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Los Angeles, CA - (NewMediaWire) - November 02, 2020 - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Fennec Pharmaceuticals Inc. (“Fennec” or “the Company”) (NASDAQ: FENC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 11, 2020 and August 10, 2020, inclusive (the ''Class Period''), are encouraged to contact the firm before November 2, 2020. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 900...

NewMediaWire | November 2, 2020

Read More 'FENC' Stories Here

FENC Price Returns

1-mo 0.68%
3-mo -3.76%
6-mo -12.02%
1-year 18.88%
3-year -18.89%
5-year N/A
YTD -0.27%
2020 14.79%
2019 1.72%
2018 -36.33%
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7246 seconds.